Live feed06:00:00·827dPRReleasevia QuantisnowCrinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly PatientsByQuantisnow·Wall Street's wire, on your screen.CRNX· Crinetics Pharmaceuticals Inc.Health Care
